heparin (UFH or LMWH)

systematic review meta-analysis network meta-analysis

Select acute coronary syndromeacute myocardial infarctionthrombosis preventionvenous thrombosis All type of patientgeneral surgeryneurosurgeryorthopedic surgeryuncoded clinical condition ***       anticoagulantextended anticoagulantextended LMWHhome treatmentlong term LMWHLow molecular weight heparinonce daily LMWHprolonged oral VKAshort term LMWHshort term UFHsubcutaneous heparinunfractionated heparin ardeparinBemiparinCertoparindalteparinenoxaparinfraxiparinheparinlogiparinnadroparinreviparintinzaparinUFHwarfarin vs discontinuationvs oral anticoagulantvs placebo or controlvs placebo or no treatmentvs aspirinvs Dextranvs heparinvs LMWHvs twice daily LMWHvs UFHvs Unfractionated heparin      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (92)Major bleeding (82)Symptomatic pulmonary embolism (51)Bleeding (48)asymptomatic DVT (46)wound haematoma / infection (45)Recurrent thromboembolic event (34)Symptomatic venous thromboembolism (DVT, PE) (25)transfusion (25)myocardial infarction or death (23)myocardial infarction (fatal and non fatal) (20)Minor bleeding (17)Short term haemorrhage (17)recurrent angina (15)Revascularization (15)VTE during active anticoagulant treatment (13)Thrombus extension (10)VTE (9)VTE during follow-up after active anticoagulant treatment (7)death at 30 days (5)myocardial infarction at 30 days (5)reinfarction (4)In-hospital death (4)death, myocardial infarction, or recurrent at 30 days (3)major or clinically relevant non-major bleeding (3)total VTE and all-cause mortality (3)death, myocardial infarction, or recurrent at 14 days (2)puylmonary embolism (2)reinfarction at 30 days (2)death at 30 days (2)stroke (fatal and non fatal) (1)Drop in platelet count of 50% (1)recurrent DVT (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	Major bleeding
acute coronary syndrome
dalteparin
FRISC (long term), 1996	dalteparin	placebo (on top of aspirin)			Low risk of bias	suggesting
FRIC prolonged treatment phase (LWMH vs PBO), 1997	dalteparin	placebo (on top of aspirin)			Low risk of bias	negative
FRISC (short term), 1996	dalteparin	placebo (on top of aspirin)			Low risk of bias	-
FRIC (acute phase LMWH vs UFH), 1997	dalteparin	UFH (on top of aspirin)			Exploratory	negative
enoxaparin
RESCUE    NCT	enoxaparin	unfractionated heparin				-
EVET, 2005	enoxaparin	tinzaparin				suggesting
ESSENCE, 1997	enoxaparin	UFH (on top of aspirin)			Low risk of bias	suggesting
TIMI 11 B (short term), 1998	enoxaparin	UFH (on top of aspirin)			Low risk of bias	suggesting
SYNERGY, 2005          NCT	enoxaparin	UFH (on top of aspirin)				negative
INTERACT, 2006	enoxaparin	UFH (on top of aspirin)				suggesting
TIMI 11 B (long term), 1998	enoxaparin	UFH (on top of aspirin)			Low risk of bias	negative
nadroparin
FRAXIS (6days), 1998	nadroparin	UFH (on top of aspirin)			Low risk of bias	negative
FRAXIS (14 days), 1998	nadroparin	UFH (on top of aspirin)			Low risk of bias	negative
UFH
Holdright, 1994	UFH	control (on top of aspirin)				negative
RISC (heparin+aspirin vs ASP), 1990	UFH	control (on top of aspirin)				negative
Theroux (heparin+ASP vs ASP), 1988	UFH	control (on top of aspirin)			Low risk of bias	suggesting
ATACS (Cohen), 1994	UFH, warfarin	control (on top of aspirin)				negative
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990	UFH, warfarin	control (on top of aspirin)				negative
Theroux (heparin vs PBO), 1988	UFH	placebo			Low risk of bias	suggesting
RISC (heparin vs PBO), 1990	UFH	placebo				negative
Theroux (heparin+aspirin vs PBO), 1988	UFH + aspirin	placebo			Low risk of bias	suggesting
RISC (ASP+ heparin vs PBO), 1990	UFH + aspirin	placebo				suggesting
Gurfinkel (UFH+aspririn vs aspirin), 1995	UFH	placebo (on top of aspirin)			Low risk of bias	negative
Cohen (ATACS pilot) (heparin vs asp), 1990	UFH, warfarin	aspirin				negative
acute myocardial infarction
enoxaparin
HART II, 2001	Enoxaparin	UFH				negative
Baird, 2002	Enoxaparin	UFH				negative
UFH
DUCCS, 1994	UFH	no heparin				negative
ECSG, 1992	UFH	placebo			Low risk of bias	negative
thrombosis prevention
ardeparin
Levine, 1996	ardeparin	placebo	knee surgery		Low risk of bias	suggesting
Godwin, 1993	ardeparin	unfractionated heparin	abdominal surgery			-
Certoparin
Schmitz-Huebner, 1984	certoparin	unfractionated heparin	abdominal surgery			negative
Sasahara, 1986	certoparin	unfractionated heparin	abdominal surgery			suggesting
Voigt, 1986	certoparin	unfractionated heparin	abdominal surgery			negative
Welzel, 1988	certoparin	unfractionated heparin	abdominal surgery			suggesting
Kakkar, 1989	certoparin	unfractionated heparin	abdominal surgery			negative
Adolf, 1989	certoparin	unfractionated heparin	abdominal surgery			negative
Heilmann, 1989	certoparin	unfractionated heparin	gynaecological surgery			negative
Baumgartner, 1989	certoparin	unfractionated heparin	abdominal surgery			negative
Hoffmann and Largiade, 1990	certoparin	unfractionated heparin	abdominal surgery			negative
Koppenhagen, 1990	certoparin	unfractionated heparin	abdominal surgery			-
Schielke, 1991	certoparin	unfractionated heparin	abdominal surgery			-
Koppenhagen, 1992	certoparin	unfractionated heparin	abdominal surgery			-
Hoffmann and Largiader, 1992	certoparin	unfractionated heparin	abdominal surgery			-
Heilmann, 1997	certoparin	unfractionated heparin	gynaecological surgery			-
Haas, 1999	certoparin	unfractionated heparin	general surgery			-
Haas , 1987	certoparine + DHE	Unfractionated heparin	hip surgery			negative
Lassen, 1988	certoparine + DHE	Unfractionated heparin	hip surgery		Low risk of bias	suggesting
Lassen, 1989	certoparine + DHE	Unfractionated heparin	hip surgery		Low risk of bias	negative
dalteparin
Jorgensen, 1989	dalteparin	placebo	hip surgery		Low risk of bias	suggesting
Torholm, 1991	dalteparin	placebo	hip surgery		Low risk of bias	suggesting
Ockelford , 1989	dalteparin	placebo				suggesting
Eriksson , 1988	dalteparin	Dextran	hip surgery			suggesting
Matzsch , 1988	dalteparin	Dextran	hip surgery			negative
Matzsch , 1991	dalteparin	Dextran	hip surgery			suggesting
Haas , 1985	dalteparin	Unfractionated heparin	hip surgery			negative
Binsack , 1986	dalteparin	Unfractionated heparin	hip surgery			negative
Barre , 1987	dalteparin	Unfractionated heparin	hip surgery			negative
Dechavanne , 1989	dalteparin	Unfractionated heparin	hip surgery			negative
Eriksson , 1989	dalteparin	Unfractionated heparin	hip surgery			suggesting
Monreal , 1989	dalteparin	Unfractionated heparin	hip surgery			negative
Bergqvist, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Onarheim, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Koller, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Koller, 1986	dalteparin	unfractionated heparin	abdominal surgery			negative
Fricker, 1988	dalteparin	unfractionated heparin	abdominal surgery			negative
Bergqvist, 1988	dalteparin	unfractionated heparin	abdominal surgery			negative
Caen, 1988	dalteparin	unfractionated heparin	abdominal surgery			negative
Borstad, 1988	dalteparin	unfractionated heparin	gynaecological surgery			negative
Briel, 1988	dalteparin	unfractionated heparin	non orthopedic surgery			negative
Creperio, 1990	dalteparin	unfractionated heparin	general surgery			negative
Hartl, 1990	dalteparin	unfractionated heparin	abdominal surgery			suggesting
Borstad, 1992	dalteparin	unfractionated heparin	gynaecological surgery			-
Kakkar, 1993	dalteparin	unfractionated heparin	abdominal surgery			-
enoxaparin
Warwick, 1995	enoxaparin	no treatment	hip surgery			negative
Ho [43]	enoxaparin	no treatment				negative
Turpie, 1986	enoxaparin	placebo	hip surgery		Low risk of bias	suggesting
Leclerc, 1991	enoxaparin	placebo	knee surgery		Low risk of bias	suggesting
Samama, 1997	enoxaparin	placebo	hip surgery		Low risk of bias	suggesting
Kalodiki, 1996	enoxaparin	placebo	hip surgery		Low risk of bias	-
Agnelli, 1998	enoxaparin	placebo				suggesting
Melon, 1987	enoxaparin	placebo				negative
DES Group , 1991	enoxaparin	Dextran	hip surgery			suggesting
Planes , 1988	enoxaparin	Unfractionated heparin	hip surgery			suggesting
Levine , 1991	enoxaparin	Unfractionated heparin	hip surgery			negative
Samama 1, 1988	enoxaparin	unfractionated heparin	general surgery			negative
Samama 2, 1988	enoxaparin	unfractionated heparin	general surgery			negative
Samama 3, 1988	enoxaparin	unfractionated heparin	general surgery			negative
Kaaja, 1992	enoxaparin	unfractionated heparin	gynaecological surgery			-
Gazzaniga (ISG), 1993	enoxaparin	unfractionated heparin	general surgery			-
Nurmohamed, 1995	enoxaparin	unfractionated heparin	general surgery			-
McLeod (Canadian), 1995	enoxaparin	unfractionated heparin	abdominal surgery			-
Gonzalez, 1996	enoxaparin	unfractionated heparin	abdominal surgery			-
ENOXACAN, 1997	enoxaparin	unfractionated heparin	abdominal surgery			-
fraxiparin
Pezzuoli, 1989	nadroparin	placebo				suggesting
Leyvraz, 1991	nadroparin	Unfractionated heparin	hip surgery			negative
nadroparin
Yoo, 1997	nadroparin	no treatment	hip surgery			negative
Marassi [41]	nadroparin	no treatment				negative
Sourmelis, 1995	nadroparin	placebo	hip surgery		Low risk of bias	suggesting
Balas [40]	nadroparin	placebo				negative
Nurmohamed, 1996	nadroparin	placebo				negative
Kakkar and Murray, 1985	nadroparin	unfractionated heparin	general surgery			suggesting
EFS, 1988	nadroparin	unfractionated heparin	abdominal surgery			suggesting
Dahan, 1989	nadroparin	unfractionated heparin	thoracic surgery			negative
Barbui, 1990	nadroparin	unfractionated heparin	general surgery			-
Eurin, 1994	nadroparin	unfractionated heparin	abdominal surgery			-
reviparin
Kakkar, 1993	reviparin	unfractionated heparin	general surgery			-
tinzaparin
Lassen, 1991	tinzaparin	placebo	hip surgery		Low risk of bias	suggesting
Bergqvist [42]	tinzaparin	placebo				negative
Leizorovicz, 1991	tinzaparin	unfractionated heparin	abdominal surgery			-
UFH
Cerrato, 1978	UFH	no treatment				suggesting
venous thrombosis
Bemiparin
Kakkar, 2003	Bemiparin	warfarin			Risk of bias	negative
dalteparin
Das, 1996	Dalteparin	warfarin			Risk of bias	negative
Lee, 2003	Dalteparin	warfarin			Risk of bias	suggesting
Holmström, 1992	once daily dalteparin	twice daily dalteparin				negative
Partsch, 1996	once daily dalteparin	twice daily dalteparin				negative
Bratt et al , 1985	Dalteparin	unfractionated heparin				negative
Holm et al , 1986	Dalteparin	unfractionated heparin				negative
Bratt et al, 1990	Dalteparin	unfractionated heparin				negative
Lindmarker et al , 1993	Dalteparin	unfractionated heparin				negative
enoxaparin
Veiga, 2000	Enoxaparin	acenocoumarol			Risk of bias	negative
González-Fajardo, 2008	Enoxaparin	coumarin			Risk of bias	-
Pini, 1994	Enoxaparin	warfarin			Risk of bias	negative
Gonzalez-Fajardo, 1999	Enoxaparin	warfarin			Risk of bias	suggesting
Meyer, 2002	Enoxaparin	warfarin			Risk of bias	negative
Deitcher, 2003	Enoxaparin	warfarin			Risk of bias	negative
Merli, 2001	once daily enoxaparin	twice daily enoxaparin			Low risk of bias	negative
Merli (once daily vs UFH), 2001	once daily enoxaparin	UFH			Low risk of bias	negative
Simonneau et al , 1993	Enoxaparin	unfractionated heparin				negative
heparin
Krahenbuhl, 1979	subcutaneous heparin	intravenous heparin				-
Bentley, 1980	subcutaneous heparin	intravenous heparin				suggesting
Andersson, 1982	subcutaneous heparin	intravenous heparin				-
Hull, 1986	subcutaneous heparin	intravenous heparin				negative
Doyle, 1987	subcutaneous heparin	intravenous heparin				negative
Walker, 1987	subcutaneous heparin	intravenous heparin				suggesting
Lopaciuk	subcutaneous heparin	intravenous heparin				negative
Pini, 1990	subcutaneous heparin	intravenous heparin				negative
logiparin
Siegbahn, 1989	once daily logiparin	twice daily logiparin				negative
nadroparin
Lopaciuk, 1999	Nadroparin	acenocoumarol			Risk of bias	negative
Lopez-Beret, 2001	Nadroparin	acenocoumarol			Risk of bias	negative
Charbonnier, 1998	once daily nadroparin	twice daily nadroparin			Low risk of bias	negative
Collaborative European Multicentre, 1991	Nadroparin	unfractionated heparin				negative
Prandoni et al , 1992	Nadroparin	unfractionated heparin				suggesting
Lopaciuk et al , 1992	Nadroparin	unfractionated heparin				negative
tinzaparin
Romera, 2009	Tinzaparin	acenocoumarol			Risk of bias	suggesting
Hull, 2002	Tinzaparin	warfarin			Risk of bias	negative
Hull et al , 1992	Tinzaparin	unfractionated heparin				suggesting
warfarin
Schulman, 1995	6 months	1.5 months				suggesting
Pinede, 2001	3-6 months	1.5-3 months				negative
Levine, 1995	warfarin	discontinuation			Low risk of bias	suggesting
LAFIT (Kearon), 1999	warfarin	discontinuation				suggesting
Agnelli, 2001	warfarin	discontinuation				negative
Agnelli, 2003	warfarin	discontinuation				negative
PREVENT (Ridker), 2003	warfarin	discontinuation				suggesting
ELAET (Kearon), 2004	warfarin	discontinuation			Low risk of bias	negative
DURAC (Schulman), 1997	warfarin	discontinuation				suggesting